Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease (ESKD) globally.
• Current treatments like RAAS blockade slow DKD progression but often fail to prevent ESKD, particularly in nonproteinuric patients.
• Emerging therapies like SGLT2 inhibitors show renal benefits, but new treatments are needed for advanced DKD.

Purpose of the Study:

• To explore the potential of pentoxifylline (PTX), a phosphodiesterase inhibitor, as a repurposed therapy for diabetic kidney disease (DKD).
• To review evidence suggesting PTX's anti-inflammatory effects may benefit patients with DKD, including those with advanced disease.
• To assess the current landscape of DKD treatment and the role of emerging and repurposed therapies.

Main Methods:

• Review of existing clinical trials and meta-analyses on pentoxifylline (PTX) in diabetic kidney disease (DKD).
• Analysis of PTX's mechanism of action, focusing on its anti-inflammatory properties and inhibition of proinflammatory cytokines.
• Consideration of ongoing large-scale clinical trials evaluating PTX for DKD progression to ESKD or death.

Main Results:

• Small randomized clinical trials and meta-analyses suggest potential therapeutic benefits of pentoxifylline (PTX) in diabetic kidney disease (DKD).
• PTX exhibits anti-inflammatory effects by inhibiting proinflammatory cytokine production, relevant to DKD pathogenesis.
• A large multicenter trial is underway to definitively assess PTX's efficacy in reducing time to ESKD or death.

Conclusions:

• Pentoxifylline (PTX) may offer a viable repurposed treatment option for diabetic kidney disease (DKD), particularly in patients with advanced disease or those not fully responding to standard care.
• While RAAS blockade and SGLT2 inhibition are current standards of care, PTX could be considered as an add-on therapy for progressive DKD.
• Further results from ongoing clinical trials are crucial to establish PTX's role in managing diabetic kidney disease (DKD) and preventing ESKD.